NASDAQ:CNSTConstellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CNST stock has decreased by 9.3% and is now trading at $29.53. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Constellation Pharmaceuticals.

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Constellation Pharmaceuticals.

Constellation Pharmaceuticals Inc (NASDAQ:CNST) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.01. View Constellation Pharmaceuticals' earnings history.

9 Wall Street analysts have issued 12-month price objectives for Constellation Pharmaceuticals' stock. Their forecasts range from $34.00 to $75.00. On average, they anticipate Constellation Pharmaceuticals' share price to reach $48.38 in the next twelve months. This suggests a possible upside of 63.8% from the stock's current price. View analysts' price targets for Constellation Pharmaceuticals.

Media coverage about CNST stock has been trending somewhat negative this week, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 1,570,000 shares, an increase of 37.7% from the May 31st total of 1,140,000 shares. Based on an average daily volume of 443,600 shares, the days-to-cover ratio is presently 3.5 days. Currently, 6.1% of the shares of the stock are short sold. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Nektar Therapeutics (NKTR), Myokardia (MYOK), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Evotec (EVTCY), Amicus Therapeutics (FOLD), GW Pharmaceuticals PLC- (GWPH), BridgeBio Pharma (BBIO), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), PTC Therapeutics (PTCT) and Agios Pharmaceuticals (AGIO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Axsome Therapeutics (AXSM), AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Crispr Therapeutics (CRSP), Enphase Energy (ENPH), Novavax (NVAX), NVIDIA (NVDA) and Provention Bio (PRVB).

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $29.53.

Constellation Pharmaceuticals has a market capitalization of $1.24 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]